Hematopoietic progenitor cell marrow therapy (Ossium Health)

N/A

Report date: 2024/04/02 18:01:50

Base Information

Drug NameHematopoietic progenitor cell marrow therapy (Ossium Health)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Donor > AllogeneicCell and gene therapy > Cell therapy > Stem cell therapy > Hematopoietic stem cells therapyCell and gene therapy > Cell therapy > Source of cells > Bone Marrow-derived
Mechanisms of ActionStem cell replacements
TargetsNot applicable
Therapy Area/IndicationsGraft vs Host DiseaseMyelodysplastic SyndromesHematologic Neoplasms +[13] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesOssium Health Inc
China Registration ClassN/A

Develop Information

Active CompaniesOssium Health Inc
Inactive CompaniesN/A
Active IndicationsGraft vs Host DiseaseMyelodysplastic SyndromesHematologic Neoplasms +[12] 
Inactive IndicationsPrecursor T-Cell Lymphoblastic Leukemia-Lymphoma

Other Information

ATC CodeN/A
Related LinksN/A